The University of Kansas Cancer Center Senior Leadership team is led by the Director, who is assisted by the Deputy Director, the Chief Operating Officer, and seven Associate Directors. The team meets bi-monthly, to discuss matters pertaining to the four research programs and their scientific progress;the four shared resources and their cost effectiveness, utilization, and quality;ad hoc budget requests from Cancer Center members;space allocation requests;new shared resources or shared equipment requests;and set all Cancer Center policies and procedures. The Senior Leaders also meet regularly in the context of the Cancer Center's Leadership Council (every other month). Program Leader (every other month) and/or Shared Resource meetings (quarterly). Collectively the Senior Leadership has ultimate responsibility for identifying, developing, and implementing intra- and inter-programmatic collaborative research opportunities. Each Senior Leader contributes a special expertise that collectively provides the Director counsel related to the development and growth of the Cancer Center's clinical trial portfolio, shared resources, basic, translational, clinical and population sciences, and research base and funding resources.

Public Health Relevance

KUCC Senior Leadership provides the vision, direction, expertise, guidance, leadership and experience that is critical to the growth, development, and success of The University of Kansas Cancer Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA168524-03
Application #
8702106
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
3
Fiscal Year
2014
Total Cost
$727,872
Indirect Cost
$510,000
Name
University of Kansas
Department
Type
DUNS #
016060860
City
Kansas City
State
KS
Country
United States
Zip Code
66160
Kumar, Dhruv; New, Jacob; Vishwakarma, Vikalp et al. (2018) Cancer-Associated Fibroblasts Drive Glycolysis in a Targetable Signaling Loop Implicated in Head and Neck Squamous Cell Carcinoma Progression. Cancer Res 78:3769-3782
Vishwakarma, Vikalp; New, Jacob; Kumar, Dhruv et al. (2018) Potent Antitumor Effects of a Combination of Three Nutraceutical Compounds. Sci Rep 8:12163
Sharma, Priyanka; López-Tarruella, Sara; García-Saenz, José Angel et al. (2018) Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. Clin Cancer Res 24:5820-5829
Snyder, Vusala; Reed-Newman, Tamika C; Arnold, Levi et al. (2018) Cancer Stem Cell Metabolism and Potential Therapeutic Targets. Front Oncol 8:203
Chen, Yvonnes; Fowler, Carina H; Papa, Vlad B et al. (2018) Adolescents' behavioral and neural responses to e-cigarette advertising. Addict Biol 23:761-771
Mudaranthakam, Dinesh Pal; Thompson, Jeffrey; Hu, Jinxiang et al. (2018) A Curated Cancer Clinical Outcomes Database (C3OD) for accelerating patient recruitment in cancer clinical trials. JAMIA Open 1:166-171
Ranjan, Atul; Iyer, Swathi V; Ward, Christopher et al. (2018) MTBP inhibits the Erk1/2-Elk-1 signaling in hepatocellular carcinoma. Oncotarget 9:21429-21443
Brody, Jonathan R; Dixon, Dan A (2018) Complex HuR function in pancreatic cancer cells. Wiley Interdiscip Rev RNA 9:e1469
Sharma, P; Barlow, W E; Godwin, A K et al. (2018) Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313). Ann Oncol 29:654-660
Campos, Camila D M; Gamage, Sachindra S T; Jackson, Joshua M et al. (2018) Microfluidic-based solid phase extraction of cell free DNA. Lab Chip 18:3459-3470

Showing the most recent 10 out of 177 publications